Amended Current Report Filing (8-k/a)
08 Settembre 2021 - 11:11PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K/A
(Amendment
No. 1)
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest reported): June 24, 2021
Novo
Integrated Sciences, Inc.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
|
001-40089
|
|
59-3691650
|
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
Number)
|
11120
NE 2nd Street, Suite 100, Bellevue, WA 98004
(Address
of principal executive offices)
(206)
617-9797
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2.)
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CF$ 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of Each Class
|
|
Trading
Symbol(s)
|
|
Name
of Each Exchange on which Registered
|
|
Common
Stock, $0.001 par value
|
|
NVOS
|
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory
Note
On
June 29, 2021, Novo Integrated Sciences, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial Form
8-K”) reporting, among other things, the closing, on June 24, 2021, of the share exchange pursuant to which Novo Healthnet Limited
(“NHL”), a wholly owned subsidiary of the Company, acquired Acenzia Inc. (“Acenzia”). This Current Report on
Form 8-K/A (Amendment No. 1) amends the Initial Form 8-K to include the historical audited financial statements of Acenzia and the pro
forma consolidated financial information required by Items 9.01(a) and 9.01(b) of Form 8-K that were excluded from the Initial Form 8-K
in reliance on the instructions to such items.
Item
9.01. Financial Statements and Exhibits.
(a)
Financial Statements of Business Acquired.
The
audited financial statements of Acenzia for the fiscal years ended April 30, 2021 and 2020 are filed herewith as Exhibit 99.1 and incorporated
herein by reference.
(b)
Pro Forma Financial Information.
The
unaudited pro forma consolidated financial information of the Company and Acenzia is filed herewith as Exhibit 99.2 and incorporated
herein by reference.
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
Novo
Integrated Sciences, Inc.
|
|
|
|
|
|
Dated:
September 8, 2021
|
By:
|
/s/
Robert Mattacchione
|
|
|
|
Robert
Mattacchione
|
|
|
|
Chief
Executive Officer
|
Grafico Azioni Novo Integrated Sciences (PK) (USOTC:NVOS)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Novo Integrated Sciences (PK) (USOTC:NVOS)
Storico
Da Gen 2024 a Gen 2025
